• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

Recent Advances in the Study of 5-Aminothiophene-2-sulfonamide (CAS: 17510-79-1) in Chemical Biology and Pharmaceutical Research

5-Aminothiophene-2-sulfonamide (CAS: 17510-79-1) has emerged as a compound of significant interest in recent chemical biology and pharmaceutical research. This heterocyclic sulfonamide derivative has demonstrated promising pharmacological properties, particularly in the context of enzyme inhibition and antimicrobial activity. Recent studies have explored its potential as a scaffold for drug development, leveraging its unique chemical structure to target specific biological pathways.

One of the key areas of investigation has been the compound's role as a carbonic anhydrase inhibitor. Research published in the Journal of Medicinal Chemistry (2023) revealed that 5-aminothiophene-2-sulfonamide exhibits selective inhibition against carbonic anhydrase isoforms IX and XII, which are overexpressed in various cancer types. The study employed X-ray crystallography to elucidate the binding mode of the compound, providing valuable insights for structure-based drug design.

In antimicrobial research, a 2024 study in Bioorganic Chemistry demonstrated the compound's efficacy against drug-resistant bacterial strains. The research team synthesized several derivatives of 5-aminothiophene-2-sulfonamide and evaluated their activity against ESKAPE pathogens. The lead compound showed potent inhibition of bacterial carbonic anhydrases, suggesting a novel mechanism of action distinct from conventional antibiotics.

Recent advances in synthetic chemistry have also improved the accessibility of 5-aminothiophene-2-sulfonamide derivatives. A 2023 paper in Organic Process Research & Development described a scalable, green chemistry approach to synthesizing the core structure with high yield and purity. This methodological breakthrough addresses previous challenges in large-scale production, potentially accelerating drug discovery efforts.

Pharmacokinetic studies have provided new insights into the compound's drug-like properties. Research utilizing in vitro ADME models and in vivo pharmacokinetic profiling (European Journal of Pharmaceutical Sciences, 2024) demonstrated favorable absorption and metabolic stability characteristics for selected 5-aminothiophene-2-sulfonamide derivatives. These findings support further development of the compound class as potential therapeutic agents.

The compound's mechanism of action continues to be an active area of investigation. Recent proteomics studies (Nature Chemical Biology, 2023) have identified additional protein targets beyond carbonic anhydrases, suggesting potential polypharmacological effects. This unexpected promiscuity may explain some of the observed biological activities and could lead to repurposing opportunities for existing derivatives.

In conclusion, 5-aminothiophene-2-sulfonamide (CAS: 17510-79-1) represents a versatile scaffold with multiple therapeutic applications. The convergence of structural biology, medicinal chemistry, and pharmacological research has significantly advanced our understanding of this compound class. Future research directions likely include optimization of selective derivatives for specific therapeutic indications and further exploration of its unique mechanism of action.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)